Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program Jul 12, 2024 10:00am EDT
Emmaus Life Sciences Receives EndariĀ® Marketing Authorization from the Bahrain NHRA May 31, 2023 2:11pm EDT